328 related articles for article (PubMed ID: 18214337)
1. Microdialysis for pharmacokinetic-pharmacodynamic studies.
Yu W; Cheng Q; Feng J; Li F
Pharmazie; 2007 Dec; 62(12):883-91. PubMed ID: 18214337
[TBL] [Abstract][Full Text] [Related]
2. PK/PD: new insights for antibacterial and antiviral applications.
Schmidt S; Barbour A; Sahre M; Rand KH; Derendorf H
Curr Opin Pharmacol; 2008 Oct; 8(5):549-56. PubMed ID: 18625339
[TBL] [Abstract][Full Text] [Related]
3. Application of microdialysis for pharmacokinetic-pharmacodynamic modelling.
Höcht C; Opezzo JA; Bramuglia GF; Taira CA
Expert Opin Drug Discov; 2006 Sep; 1(4):289-301. PubMed ID: 23495900
[TBL] [Abstract][Full Text] [Related]
4. In vivo microdialysis for PK and PD studies of anticancer drugs.
Zhou Q; Gallo JM
AAPS J; 2005 Oct; 7(3):E659-67. PubMed ID: 16353942
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
[TBL] [Abstract][Full Text] [Related]
6. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.
Toutain PL; Lees P
J Vet Pharmacol Ther; 2004 Dec; 27(6):467-77. PubMed ID: 15601441
[TBL] [Abstract][Full Text] [Related]
7. Microdialysis: a technique for pharmacokinetic-pharmacodynamic studies of oncological drugs.
Wei YH; Xu LZ; Shen Q; Li FZ
Curr Pharm Biotechnol; 2009 Sep; 10(6):631-40. PubMed ID: 19619119
[TBL] [Abstract][Full Text] [Related]
8. Microdialysis: an in vivo approach for measuring drug delivery in oncology.
Brunner M; Müller M
Eur J Clin Pharmacol; 2002 Jul; 58(4):227-34. PubMed ID: 12136367
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic biomarkers for molecular cancer therapeutics.
Sarker D; Workman P
Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
[TBL] [Abstract][Full Text] [Related]
10. PK/PD modelling and simulations: utility in drug development.
Rajman I
Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
[TBL] [Abstract][Full Text] [Related]
11. Lung microdialysis--a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review).
Zeitlinger M; Müller M; Joukhadar C
AAPS J; 2005 Oct; 7(3):E600-8. PubMed ID: 16353939
[TBL] [Abstract][Full Text] [Related]
12. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
Bellissant E; Courcier-Duplantier S; Blin O;
Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
[TBL] [Abstract][Full Text] [Related]
13. Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies.
Workman P; Aboagye EO; Chung YL; Griffiths JR; Hart R; Leach MO; Maxwell RJ; McSheehy PM; Price PM; Zweit J;
J Natl Cancer Inst; 2006 May; 98(9):580-98. PubMed ID: 16670384
[TBL] [Abstract][Full Text] [Related]
14. Intracerebral microdialysis technique and its application on brain pharmacokinetic-pharmacodynamic study.
Pan YF; Feng J; Cheng QY; Li FZ
Arch Pharm Res; 2007 Dec; 30(12):1635-45. PubMed ID: 18254253
[TBL] [Abstract][Full Text] [Related]
15. Microdialysis in clinical drug delivery studies.
Müller M
Adv Drug Deliv Rev; 2000 Dec; 45(2-3):255-69. PubMed ID: 11108978
[TBL] [Abstract][Full Text] [Related]
16. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
Mouton JW; Dudley MN; Cars O; Derendorf H; Drusano GL
J Antimicrob Chemother; 2005 May; 55(5):601-7. PubMed ID: 15772142
[TBL] [Abstract][Full Text] [Related]
17. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs.
Brunner M; Derendorf H; Müller M
Curr Opin Pharmacol; 2005 Oct; 5(5):495-9. PubMed ID: 16084767
[TBL] [Abstract][Full Text] [Related]
18. PK-PD modeling of protein drugs: implications in assay development.
Roskos LK; Schneider A; Vainshtein I; Schwickart M; Lee R; Lu H; Faggioni R; Liang M
Bioanalysis; 2011 Mar; 3(6):659-75. PubMed ID: 21417734
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
Luu KT; Zhang EY; Prasanna G; Xiang C; Anderson S; Fortner J; Vicini P
J Pharmacol Exp Ther; 2009 Nov; 331(2):627-35. PubMed ID: 19690190
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.
Varghese JM; Roberts JA; Lipman J
Crit Care Clin; 2011 Jan; 27(1):19-34. PubMed ID: 21144984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
